2 Of King's Skelaxin Patents Invalidated

Law360, New York (January 21, 2009, 12:00 AM EST) -- A federal judge has invalidated two of King Pharmaceuticals Inc.'s patents that cover the muscle relaxant Skelaxin, although the company still has one patent for the drug not affected by the decision.

In an order issued Tuesday, Judge David G. Trager of the U.S. District Court for the Eastern District of New York granted Eon Labs Inc.'s motion for summary judgment, saying the patents were invalid on anticipation and obviousness grounds.

Metaxalone, the active ingredient in Skelaxin, has been around since the early 1960s, and the...
To view the full article, register now.